Nicox’s NCX 470 Hits Phase III Endpoint In Glaucoma But Misses Superiority

Nicox S.A. posted mostly favorable Phase III data from the first of two pivotal trials for its glaucoma/ocular hypertension eye drop NCX 470, but missed demonstrating superiority versus a comparator that could have positioned the candidate to become a new standard of care.

The French company revealed on 31 October that NCX 470 – a formulation of the prostaglandin analog bimatoprost, the active ingredient in AbbVie Inc.’s Lumigan, paired with nitric oxide-donating technology – met the primary endpoint in the 691-patient Phase III Mont Blanc study for non-inferiority to comparator latanoprost in reducing intraocular pressure (IOP) from baseline. A 0.1% dose of NCX 470 reduced IOP by 8.0-9